PMID- 37065961
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230418
IS  - 0019-5049 (Print)
IS  - 0976-2817 (Electronic)
IS  - 0019-5049 (Linking)
VI  - 67
IP  - Suppl 1
DP  - 2023 Feb
TI  - Role of gabapentinoids in post-operative pain management in thoracic surgeries: A 
      single-centre propensity score-matched audit.
PG  - S35-S40
LID - 10.4103/ija.ija_498_22 [doi]
AB  - BACKGROUND AND AIMS: The analgesic role of gabapentinoids following thoracic 
      surgeries is not clear. In this study, we evaluated the benefits of 
      gabapentinoids for pain management in patients undergoing thoracic onco-surgery 
      in terms of opioids and non-steroidal anti-inflammatory drugs (NSAIDs) sparing 
      effect. We also compared pain scores (PSs), number of days of active surveillance 
      by the acute pain service team, and side effects associated with gabapentinoids. 
      METHODS: After ethics-committee approval, data were retrieved retrospectively 
      from clinical sheets, an electronic database, and nurses' charts from a tertiary 
      cancer care hospital. Propensity score matching was performed for six covariates, 
      that is, age, gender, American Society of Anesthesiologists grading, surgical 
      approach, analgesia modality, and worst PS in the first 24 hours performed. A 
      total of 272 patients were grouped into group N (not given gabapentinoids, n = 
      174) and group Y (given, n = 98). RESULTS: The median opioid consumption in terms 
      of fentanyl equivalent by group N was 800 microg [inter-quartile range (IQR): 
      280-900], and the median opioid consumption by group Y was 400 microg (IQR: 100-690) 
      (p = 0.001). The median number of rescue doses of NSAIDs administered to group N 
      was 8 (IQR = 4-10), and the median number of rescue doses to group Y was 3 (IQR = 
      2-5) (p = 0.001). No difference was found in subsequent PS and for the number of 
      days under acute pain service surveillance for either group. Group Y had an 
      increased incidence of giddiness compared to group N (p = 0.006), with a relative 
      reduction in post-operative nausea and vomiting scores (p = 0.32). CONCLUSION: 
      Gabapentinoids used following thoracic onco-surgeries result in a significant 
      reduction in concomitant use of NSAIDs and opioids. There is an increased 
      incidence of dizziness with the use of these drugs.
CI  - Copyright: (c) 2023 Indian Journal of Anaesthesia.
FAU - Karkhanis, Dhanashri R
AU  - Karkhanis DR
AD  - Department of Anaesthesiology, Critical Care Medicine and Pain, Tata Memorial 
      Hospital and Homi Bhabha National Institute, Parel, Mumbai, Maharashtra, India.
FAU - Bakshi, Sumitra G
AU  - Bakshi SG
AD  - Department of Anaesthesiology, Critical Care Medicine and Pain, Tata Memorial 
      Hospital and Homi Bhabha National Institute, Parel, Mumbai, Maharashtra, India.
FAU - Divatia, Jigeeshu V
AU  - Divatia JV
AD  - Department of Anaesthesiology, Critical Care Medicine and Pain, Tata Memorial 
      Hospital and Homi Bhabha National Institute, Parel, Mumbai, Maharashtra, India.
FAU - Kannan, Sadhana
AU  - Kannan S
AD  - Department of Anaesthesiology, Critical Care Medicine and Pain, Tata Memorial 
      Hospital and Homi Bhabha National Institute, Parel, Mumbai, Maharashtra, India.
LA  - eng
PT  - Journal Article
DEP - 20230210
PL  - India
TA  - Indian J Anaesth
JT  - Indian journal of anaesthesia
JID - 0013243
PMC - PMC10104085
OTO - NOTNLM
OT  - Adverse effects
OT  - gabapentin
OT  - pain management
OT  - pregabalin
COIS- There are no conflicts of interest.
EDAT- 2023/04/18 06:00
MHDA- 2023/04/18 06:01
PMCR- 2023/02/01
CRDT- 2023/04/17 04:03
PHST- 2022/06/07 00:00 [received]
PHST- 2022/09/21 00:00 [revised]
PHST- 2023/01/28 00:00 [accepted]
PHST- 2023/04/18 06:01 [medline]
PHST- 2023/04/17 04:03 [entrez]
PHST- 2023/04/18 06:00 [pubmed]
PHST- 2023/02/01 00:00 [pmc-release]
AID - IJA-67-35 [pii]
AID - 10.4103/ija.ija_498_22 [doi]
PST - ppublish
SO  - Indian J Anaesth. 2023 Feb;67(Suppl 1):S35-S40. doi: 10.4103/ija.ija_498_22. Epub 
      2023 Feb 10.